|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4 Suppl
|
|
pubmed:dateCreated |
2006-6-13
|
|
pubmed:abstractText |
Immunotherapy with Bacillus Calmette Guerin (BCG) has been widely used recently as primary option for treatment of high grade superficial (G3T1) carcinoma of the bladder. We describe our long term experience of therapy of G3T1 bladder cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0392-9078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
223-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16767936-Administration, Intravesical,
pubmed-meshheading:16767936-Adult,
pubmed-meshheading:16767936-Aged,
pubmed-meshheading:16767936-Aged, 80 and over,
pubmed-meshheading:16767936-Carcinoma, Transitional Cell,
pubmed-meshheading:16767936-Disease Progression,
pubmed-meshheading:16767936-Female,
pubmed-meshheading:16767936-Humans,
pubmed-meshheading:16767936-Immunotherapy,
pubmed-meshheading:16767936-Male,
pubmed-meshheading:16767936-Middle Aged,
pubmed-meshheading:16767936-Mycobacterium bovis,
pubmed-meshheading:16767936-Neoplasm Recurrence, Local,
pubmed-meshheading:16767936-Survival Rate,
pubmed-meshheading:16767936-Treatment Outcome,
pubmed-meshheading:16767936-Urinary Bladder Neoplasms
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
|
|
pubmed:affiliation |
Vincenzo Pansadoro Foundation and San Giovanni Hospital, Rome, Italy. paoloemiliozzi@hotmail.com
|
|
pubmed:publicationType |
Journal Article
|
